CTRI/2022/05/042617
Not yet recruiting
Phase 2
â??A double-blind, placebo-controlled, comparative clinical study followed by an Open-label extension study, to evaluate the efficacy and safety of PartySmart Soft Chewsâ??
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Himalaya Wellness Company
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Male and female subjects aged between 20\-50 years, weighing more than 45 kgs.
- •2\. Subjects who used to drink alcohol regularly (social drink, but not alcohol abuse) and is willing and able to comply with the alcohol consumption, blood withdrawal requirements and overnight stay as per the study requirements.
- •3\. Subjects judged by the Investigator to be in general good health based on medical history.
- •4\. Subjects understand the study procedures and sign the informed consent forms to participate in the study
Exclusion Criteria
- •1 Subjects suspected for drug or alcohol abuse.
- •2\. A medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation.
- •3\. Subjective sleep duration of less than 3 hours in the night before every study period.
- •4\. Caffeine, nicotine on the day (from midnight) of the every study Period.
- •5\. Alcohol consumption within 7 days of enrollment in the study
- •6\. Use of psycho\-active drugs during the past 30 days or any treatment that might interfere with the evaluation of the test drug.
- •7\. Subjects taking any drug known to interact with benzodiazepines and other drugs, e.g. antiepileptics, antihistamines, muscle relaxant drugs, antihypertensive drugs, drugs inhibiting cytochrome P450\.
- •8\. Subjects suffering from any clinically significant disorder that might interfere with his/her participation in this study and the evaluation of the efficacy or safety of the test drug (e.g. renal insufficiency, hepatic or metabolic dysfunction, cardiovascular disease, neurological and or psychiatric disorder etc.).
- •9\. Known hypersensitivity to any of the ingredients of the study drugs.
- •10\. Participation in any other clinical trial within the past 30 days.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Flora to provide confirmation: A study evaluating the efficacy of QGE031 compared to omalizumab in patients with allergic asthma.asthmaMedDRA version: 14.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2012-003350-84-SEovartis Pharma Services AG40
Completed
Not Applicable
A placebo controlled, double blind, comparative trial concerning safety verification of long-term intake of protein hydrolyzateHealthy adultsJPRN-UMIN000052861IMEQRD Co., Ltd30
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo comparative clinical trial to evaluate the functionality and safety of KPE01 and KPE02 for body fat reduction in overweight or obese adults.Endocrine, nutritional and metabolic diseasesKCT0007879Semyung University150
Unknown
Phase 2
A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.Down SyndromeJPRN-jRCT2080222131Eisai Co., Ltd.60
Completed
Not Applicable
se of vitamin C tablet in the prophylaxis of bacterial vaginosis relapsesISRCTN77890633Polichem SA (Switzerland)142